SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (516)11/14/1999 11:56:00 PM
From: RCMac  Read Replies (1) of 626
 
TTP's pipeline, in addition to Zomaril, includes:

(1) its Spheramine cell therapy for Parkinson's, see: Message 11472882 (press release re NIH grant for spheramine program), and Message 11495848 (Neuroinvestment comments on program, including: "Titan has shifted the bulk of its preclinical energy to the Spheramine program"),

(2) Pivanex, a cancer therapeutic for non-small cell lung cancer and potentially other cancers, see Message 7371893 (possibly backburnered?);

(3) several cancer vaccine programs, possibly also backburnered; and

(4) something to do with Sertoli cells, see: Message 11490207

I'm not a scientist, and have little basis for judging whether any of these shows any promise, but from the opinions on SI and elsewhere of those whose scientific judgment I've come to trust, my guess is that nothing in the pipe has any value, with the possible exception of the Spheramine/Parkinson's project.

None of these pipeline items appears to have any effect on the stock's current price; but announcement of a rumored big pharma partnership for the Spheramine/Parkinson's project could certainly drive the stock up.

Assuming that all the warrants are converted by the 11/19 deadline, TTP will have another $44 million in cash to devote to this pipeline.

Hope this is helpful.

--RCM
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News